...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: BIO Investor Forum, Oct 22-23

Given the radio silence that RVX has imposed on itself, any idea what they will say in San Francisco in the next 2 days? 

 

 

Share
New Message
Please login to post a reply